Biotechnology
CMO/CDMO Biotechnology Market

CMO/CDMO Biotechnology Market Size, Share, and Growth Forecast, 2025 - 2032

CMO/CDMO Biotechnology Market By Service Type (Standalone Services, Others), Product Type (Monoclonal Antibodies, Cell & Gene Therapies (CGTs), Others), Scale of Operation (Small Scale/Pilot Production, Large Scale/Commercial Manufacturing), and Regional Analysis for 2025 - 2032

ID: PMRREP32516

October 2025

191 Pages

Author : Pravin Rewale

Healthcare

Preview Segmentation

Key Industry Highlights

Dominant & Fastest-growing Product Types: Monoclonal antibodies are expected to hold an estimated 45% share in 2025, while cell & gene therapies will grow the fastest with a 15% CAGR from 2025 to 2032.
Fastest-growing Service Type: Integrated contract development and manufacturing services are the fastest expanding service type, reflecting pharmaceutical companies’ increasing demand for one-stop solutions.
Fastest-growing Regional Market: Asia Pacific is the fastest-growing regional market, with a CAGR of about 14%, leveraging policy incentives, cost advantages, and rising R&D investments.
Leading Region: North America commands the largest regional market share of approximately 42% in 2025, supported by FDA-driven progressive regulatory frameworks and innovation ecosystems.
Players’ Focus: Key players are focusing on capacity expansions, digital transformation in manufacturing, and strategic acquisitions to consolidate market presence and meet the complex demand for biologics.
Major Opportunity: Emerging CDMO hubs in Asia Pacific offer significant opportunities owing to cost-effectiveness, regulatory reforms, and growing contract research and manufacturing demands.
September 2025: Lotte Biologics landed a contract with an unnamed U.S. pharmaceutical company to manufacture a Phase 3 asset, and if it gains approval, the agreement will extend into commercial production through 2030.

Key Insights	Details
CMO/CDMO Biotechnology Market Size (2025E)	US$74.0 Bn
Market Value Forecast (2032F)	US$168.9 Bn
Projected Growth (CAGR 2025 to 2032)	12.5%
Historical Market Growth (CAGR 2019 to 2024)	11%

Get Your CustomizationGet Your Customization

Market Factors - Growth, Barriers, and Opportunity Analysis

Demand Surge for Complex Biologic Therapeutics

The expanding pipeline of complex biologics, including monoclonal antibodies (mAbs), recombinant proteins, and cell & gene therapies (CGT), is a fundamental determinant for the market growth. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved an increasing number of biologics and biosimilars over the last few years, signaling heightened outsourcing needs for development and manufacturing capacity. Advanced expression systems and disposable bioreactors enhance process flexibility, enabling scalable, contamination-reducing manufacture at lower costs. The sustained dependence of biopharma companies on CDMOs is reinforced by their consistently rising yearly R&D expenditure, emphasizing the adoption of external expertise to accelerate market delivery and mitigate investment risk associated with in-house manufacturing complexities.

Regulatory Compliance and Quality Assurance Costs

Stringent regulatory compliance across multiple jurisdictions remains a significant barrier, creating structural complexity and elevated costs for CDMOs. Adherence to GMP standards, coupled with varying regional mandates for process validation, documentation, and quality assurance, imposes operational burdens. Non-compliance risks include fines, recalls, and potential contract loss, impacting revenue predictability. For example, delays caused by Investigational New Drug (IND) or New Drug Application (NDA) approvals can extend project timelines by several months, causing considerable cost upheavals.

Moreover, overly strict regulatory inspections necessitate continuous capital infusion in upgrading facilities, staff training, and certification renewals. Such obstacles challenge mid-sized and emerging CDMOs disproportionately, limiting their scaling capabilities. Consequently, regulatory complexity acts as a demand bottleneck while encouraging market consolidation among established service providers with compliant infrastructure and robust quality systems.

Digital Transformation in Bioprocessing and Smart Manufacturing

The digital transformation of bioprocessing and manufacturing represents a compelling untapped opportunity within the market, driven by advances in Industry 4.0 technologies, including Artificial Intelligence (AI), machine learning, Internet of Things (IoT), and big data analytics. These technologies are enabling smart biomanufacturing environments characterized by real-time monitoring, predictive maintenance, and process optimization, which significantly increase operational efficiency, reduce batch failures, and improve product quality consistency. Digital twin platforms and cloud-based process analytics further facilitate remote supervision and scalability of complex biologics production.

This digital shift is especially relevant for advanced therapies where process variability and customization demands are high. Pharmaceutical companies increasingly seek CDMOs capable of integrating digital bioprocessing for faster, data-driven decisions aligned with regulatory compliance mandates such as the FDA’s Process Analytical Technology (PAT) framework. This convergence fosters new service models, including continuous manufacturing as a service, boosted by digital oversight. Early investments in digital infrastructure and workforce upskilling thus position players for sustainable long-term growth and differentiation in a crowded outsourcing landscape.

Category-wise Analysis

Service Type Insights

Standalone services are set to dominate with an estimated 60% of the CMO/CDMO biotechnology market share in 2025, aided by a growing demand for specialized solutions such as cell-line development, analytical testing, and fill-finish services. Pharmaceutical companies frequently prefer outsourcing discrete high-skill or capital-intensive services rather than fully integrated manufacturing, especially in early-stage development or for clinical trial material production. This preference allows flexibility in vendor selection and reduces exposure to single-source dependencies.

However, as market dynamics shift, integrated development and manufacturing services are forecasted to grow at an accelerated CAGR between 2025 and 2032. This strong upward trajectory is propelled by pharmaceutical companies’ increasing inclination for outsourcing comprehensive drug development lifecycles, from early discovery through commercial-scale manufacturing, to streamline regulatory submissions, reduce timeline inefficiencies, and leverage economies of scale. Mid-size CDMOs with modular, technology-flexible platforms are capitalizing on this trend as sponsors seek partners capable of agile response to clinical pipeline fluctuations and personalized medicines.

Product Type Insights

Monoclonal antibodies are slated to secure the leading position with an estimated 45% market share in 2025, due to their clinical maturity, broad therapeutic applications across oncology, autoimmune disorders, and inflammation, and operational scalability in contract manufacturing. Their robust demand sustains large-volume outsourcing, benefiting from standardized production platforms and well-established regulatory pathways.

In contrast, cell and gene therapies (CGTs) represent the fastest-growing product category with a projected CAGR exceeding 15% through 2032. The explosive growth of this segment is fueled by breakthrough approvals of CAR-T therapies and viral vector-based gene therapies, alongside rising investments in personalized medicine and rare disease treatments. CGTs necessitate specialized facilities with advanced viral vector manufacturing capabilities, single-use bioreactor systems, and stringent cold chain logistics, creating high entry barriers but lucrative opportunities for CDMOs expanding these platforms.

Scale of Operation Insights

Large scale/Commercial manufacturing is likely to capture the lion’s share of outsourcing contracts at an estimated 65% in 2025, reflecting the need for large batch productions and cost efficiencies for mature biologics and biosimilars. Large-scale CDMOs benefit from economies of scale, infrastructure investments, and long-term client contracts, enabling robust revenue and capacity utilization.

The small-scale/pilot production segment is expected to register the highest CAGR from 2025 to 2032, on account of a speedily increasing number of early-phase clinical trials and personalized medicine manufacturing demand. Flexible, modular, single-use bioprocessing technologies allow CDMOs to offer nimble, cost-effective production runs tailored to smaller patient populations or bespoke therapies. Investments in pilot-scale capacity also attract biopharma startups seeking to outsource early clinical batch manufacturing, contributing to market fragmentation and expansion at the lower end of the capacity spectrum.

global-cmo-cdmo-biotechnology-market-outlook-by-product-type

Request Free sampleRequest Free sample

Regional Insights

North America CMO/CDMO Biotechnology Market Trends

North America is anticipated to lead with an estimated 42% of the CMO/CDMO biotechnology market share in 2025, driven by the United States’ dominant biopharma landscape. The robust CAGR of the regional market is stimulated by a steady growth of the healthcare innovation ecosystem, regulatory modernization from the FDA, and dense concentration of large biotech hubs, including Boston, San Francisco, and San Diego. The FDA’s expedited regulatory pathways, adaptive trial designs, and digital inspection initiatives lower barriers for contract manufacturing integration.

CDMOs in North America benefit from early adoption of advanced bioprocess technologies, digital biomanufacturing, and comprehensive quality systems to meet stringent regulatory expectations. Strategic investments focus on capacity expansions and digitization, while M&A activity remains robust as larger CDMOs consolidate expertise and facilities. However, rising labor and operational costs pose challenges, encouraging pharmaceutical companies to diversify supply chains and invest selectively in onshore capacity.

Europe CMO/CDMO Biotechnology Market Trends

Europe is set to command approximately 25% of the market share in 2025, with Germany, the U.K., France, and Spain as major contributors. The regional market is fueled by regulatory harmonization led by the EMA that facilitates cross-border clinical trial conduct and manufacturing service deployment. European CDMOs emphasize quality assurance, GMP compliance, and high-value specialized services, particularly in gene editing and biosimilars manufacturing niches. Investment trends reveal growing commitments to digital transformation, automation, and bioprocess intensification technologies, supported by EU funding programs such as Horizon Europe.

The regulatory landscape, while rigorous, is providing clearer guidance on advanced therapy medicinal products (ATMPs), enhancing the adoption of outsourcing solutions. The competitive environment features a mix of historical contract manufacturers and innovative biotech-focused CDMOs expanding through strategic partnerships. Market maturation encourages integration of sustainability initiatives, green manufacturing, and digital traceability to align with EU policy objectives.

Asia Pacific CMO/CDMO Biotechnology Market Trends

Asia Pacific is slated to emerge as the fastest-growing regional market with a projected CAGR of 14% through 2032. The CMO/CDMO biotechnology market growth here is predominantly concentrated in China, India, South Korea, and an expanding ASEAN footprint, leveraging competitive labor costs, government incentives, including tax holidays and streamlined approval processes, and expanded investment in enabling infrastructure. China’s biotech ecosystem has experienced a tripling of biopharma R&D expenditure since 2020, with foreign and domestic CDMOs increasing manufacturing capacity and capabilities, including viral vector and single-use systems.

India’s evolving regulatory framework and vast clinical trial patient pool attract global sponsors outsourcing both clinical supplies and commercial biologics manufacturing. South Korea’s established manufacturing expertise, underscored by Samsung Biologics and Celltrion expansions, anchors the regional market. Regulatory reforms to harmonize standards and increase approval speed are further enhancing Asia Pacific’s competitive positioning. The region is increasingly attracting cross-border collaborations and strategic investments, supporting its evolution as a critical global CDMO hub.

global-cmo-cdmo-biotechnology-market-outlook-by-region

Competitive Landscape

The global CMO/CDMO biotechnology market is moderately consolidated, with the top 10 players holding about 58% share. Key leaders such as Lonza, Thermo Fisher Scientific, Samsung Biologics, Boehringer Ingelheim, and AGC Biologics leverage extensive service portfolios and global reach to deliver end-to-end biomanufacturing solutions. Smaller CDMOs focus on niche therapies and flexible partnerships, driving innovation. Active M&A continues to shape the market, enabling capacity expansion, service diversification, and broader geographic reach. This balance of scale and specialization underpins sustainable growth across the biopharma outsourcing ecosystem.

Key Industry Developments

In September 2025, Amaran Biotech won the “Best Fill-Finish” award at the Asia Pacific Biologics CDMO Excellence Awards in Singapore, recognizing its advanced aseptic fill-finish capabilities for high-value biologics. The Taiwanese CDMO, which launched the nation’s first fully automated fill-finish line in 2022, exemplifies Taiwan’s rising prominence in global biopharmaceutical manufacturing and Amaran’s commitment to innovation and international quality standards.
In June 2025, Zydus Lifesciences announced the acquisition of two US biologics facilities from Agenus Inc. in California for US$75 million, marking its entry into the global biologics CDMO market. The deal provides Zydus with advanced manufacturing capabilities, a strategic presence in a leading biotech hub, exclusive manufacturing rights for two Phase-3 immuno-oncology products, and first rights to future pipeline molecules.
In May 2025, IdeeLab became a full-service CDMO, launching a Brazil facility with 1 million liters of annual capacity. Designed for agricultural biological, biofertilizers, biostimulants, biocontrol agent, the plant can produce microorganisms, recombinant proteins, peptides, and RNAi products, enabling access to key farming markets and a growing ag-biologicals sector.

Companies Covered in CMO/CDMO Biotechnology Market

Lonza Group AG
Thermo Fisher Scientific Inc.
Samsung Biologics Co., Ltd.
Boehringer Ingelheim International GmbH
AGC Biologics, Inc.
WuXi Biologics
Patheon N.V.
Catalent, Inc.
AbbVie Inc.
Avid Bioservices, Inc.
Fujifilm Diosynth Biotechnologies
Rentschler Biopharma SE
KBI Biopharma (JSR Corporation)
Cytovance Biologics
Xpress Biologic

Frequently Asked Questions

The CMO/CDMO biotechnology market is projected to reach US$74.0 Billion in 2025.

The increasing reliance of pharmaceutical and biopharmaceutical companies on outsourcing for innovative biologics and advanced therapeutic production is driving the market.

The CMO/CDMO biotechnology market is poised to witness a CAGR of 12.5% from 2025 to 2032.

An escalating demand for cost-effective, scalable manufacturing solutions for novel biologics, biosimilars, and gene therapies, technological advancements such as single-use bioreactors, and capacity expansion investment by CDMOs are key market opportunities.

Lonza Group AG, Thermo Fisher Scientific, and Samsung Biologics are some of the key players in the CMO/CDMO biotechnology market.

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis	Value: US$ Bn
Geographical Coverage	North America Europe East Asia South Asia & Oceania Latin America Middle East & Africa
Segmental Coverage	Service Type Product Type Scale of Operation
Competitive Analysis	Lonza Group AG Thermo Fisher Scientific Inc. Samsung Biologics Co., Ltd. Boehringer Ingelheim International GmbH AGC Biologics, Inc. WuXi Biologics Patheon N.V. Catalent, Inc. AbbVie Inc. Avid Bioservices, Inc. Fujifilm Diosynth Biotechnologies Rentschler Biopharma SE KBI Biopharma (JSR Corporation) Cytovance Biologics Xpress Biologic
Report Highlights	Market Forecast & Trends Competitive Intelligence & Share Analysis Growth Factors & Challenges Strategic Growth Initiatives Pricing Analysis Future Opportunities & Revenue Pockets Market Analysis Tools

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Key Insights

Details

CMO/CDMO Biotechnology Market Size (2025E)

US$74.0 Bn

Market Value Forecast (2032F)

US$168.9 Bn

Projected Growth (CAGR 2025 to 2032)

12.5%

Historical Market Growth (CAGR 2019 to 2024)

11%

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis	Value: US$ Bn
Geographical Coverage	North America Europe East Asia South Asia & Oceania Latin America Middle East & Africa
Segmental Coverage	Service Type Product Type Scale of Operation
Competitive Analysis	Lonza Group AG Thermo Fisher Scientific Inc. Samsung Biologics Co., Ltd. Boehringer Ingelheim International GmbH AGC Biologics, Inc. WuXi Biologics Patheon N.V. Catalent, Inc. AbbVie Inc. Avid Bioservices, Inc. Fujifilm Diosynth Biotechnologies Rentschler Biopharma SE KBI Biopharma (JSR Corporation) Cytovance Biologics Xpress Biologic
Report Highlights	Market Forecast & Trends Competitive Intelligence & Share Analysis Growth Factors & Challenges Strategic Growth Initiatives Pricing Analysis Future Opportunities & Revenue Pockets Market Analysis Tools

Executive Summary
1. Global CMO/CDMO Biotechnology Market Snapshot, 2025 and 2032
2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Product Type Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Key Trends
3. Macro-economic Factors
  1. Global Sectoral Outlook
  2. Global GDP Growth Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. Tool Adoption Analysis
2. Regulatory Landscape
3. Value Chain Analysis
4. PESTLE Analysis
5. Porter’s Five Force Analysis
Price Analysis, 2024A
1. Key Highlights
2. Key Factors Impacting Deployment Costs
3. Pricing Analysis, By Product Type
Global CMO/CDMO Biotechnology Market Outlook
1. Key Highlights
  1. Market Volume (Units) Projections
  2. Market Size (US$ Bn) and Y-o-Y Growth
  3. Absolute $ Opportunity
2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
  1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
3. Global CMO/CDMO Biotechnology Market Outlook: Service Type
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Service Type, 2019 - 2024
  3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
    1. Standalone Services
    2. Integrated Contract Development & Manufacturing Services
    3. Contract Manufacturing Services
  4. Market Attractiveness Analysis: Service Type
4. Global CMO/CDMO Biotechnology Market Outlook: Product Type
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019 - 2024
  3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
    1. Monoclonal Antibodies
    2. Cell & Gene Therapies (CGTs)
    3. Advanced Therapy Medicinal Products (ATMPs)
    4. Others
  4. Market Attractiveness Analysis: Product Type
5. Global CMO/CDMO Biotechnology Market Outlook: Scale of Operation
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019 - 2024
  3. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
    1. Small Scale/Pilot Production
    2. Large Scale/Commercial Manufacturing
  4. Market Attractiveness Analysis: Scale of Operation
Global CMO/CDMO Biotechnology Market Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019 - 2024
3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025 - 2032
  1. North America
  2. Europe
  3. East Asia
  4. South Asia and Oceania
  5. Latin America
  6. Middle East & Africa
4. Market Attractiveness Analysis: Region
North America CMO/CDMO Biotechnology Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Service Type
  3. By Product Type
  4. By Scale of Operation
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. U.S.
  2. Canada
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
  1. Standalone Services
  2. Integrated Contract Development & Manufacturing Services
  3. Contract Manufacturing Services
5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
  1. Monoclonal Antibodies
  2. Cell & Gene Therapies (CGTs)
  3. Advanced Therapy Medicinal Products (ATMPs)
  4. Others
6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
  1. Small Scale/Pilot Production
  2. Large Scale/Commercial Manufacturing
7. Market Attractiveness Analysis
Europe CMO/CDMO Biotechnology Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Service Type
  3. By Product Type
  4. Scale of Operation
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Russia
  7. Türkiye
  8. Rest of Europe
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
  1. Standalone Services
  2. Integrated Contract Development & Manufacturing Services
  3. Contract Manufacturing Services
5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
  1. Monoclonal Antibodies
  2. Cell & Gene Therapies (CGTs)
  3. Advanced Therapy Medicinal Products (ATMPs)
  4. Others
6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
  1. Small Scale/Pilot Production
  2. Large Scale/Commercial Manufacturing
7. Market Attractiveness Analysis
East Asia CMO/CDMO Biotechnology Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Service Type
  3. By Product Type
  4. By Scale of Operation
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. China
  2. Japan
  3. South Korea
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
  1. Standalone Services
  2. Integrated Contract Development & Manufacturing Services
  3. Contract Manufacturing Services
5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
  1. Monoclonal Antibodies
  2. Cell & Gene Therapies (CGTs)
  3. Advanced Therapy Medicinal Products (ATMPs)
  4. Others
6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
  1. Small Scale/Pilot Production
  2. Large Scale/Commercial Manufacturing
7. Market Attractiveness Analysis
South Asia & Oceania CMO/CDMO Biotechnology Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Service Type
  3. By Product Type
  4. By Scale of Operation
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of South Asia & Oceania
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
  1. Standalone Services
  2. Integrated Contract Development & Manufacturing Services
  3. Contract Manufacturing Services
5. ICurrent Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
  1. Monoclonal Antibodies
  2. Cell & Gene Therapies (CGTs)
  3. Advanced Therapy Medicinal Products (ATMPs)
  4. Others
6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
  1. Small Scale/Pilot Production
  2. Large Scale/Commercial Manufacturing
7. Market Attractiveness Analysis
Latin America CMO/CDMO Biotechnology Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Service Type
  3. By Product Type
  4. By Scale of Operation
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. Brazil
  2. Mexico
  3. Rest of Latin America
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
  1. Standalone Services
  2. Integrated Contract Development & Manufacturing Services
  3. Contract Manufacturing Services
5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
  1. Monoclonal Antibodies
  2. Cell & Gene Therapies (CGTs)
  3. Advanced Therapy Medicinal Products (ATMPs)
  4. Others
6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
  1. Small Scale/Pilot Production
  2. Large Scale/Commercial Manufacturing
7. Market Attractiveness Analysis
Middle East & Africa CMO/CDMO Biotechnology Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Service Type
  3. By Product Type
  4. By Scale of Operation
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. GCC Countries
  2. Egypt
  3. South Africa
  4. Northern Africa
  5. Rest of Middle East & Africa
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
  1. Standalone Services
  2. Integrated Contract Development & Manufacturing Services
  3. Contract Manufacturing Services
5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
  1. Monoclonal Antibodies
  2. Cell & Gene Therapies (CGTs)
  3. Advanced Therapy Medicinal Products (ATMPs)
  4. Others
6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
  1. Small Scale/Pilot Production
  2. Large Scale/Commercial Manufacturing
7. Market Attractiveness Analysis
Competition Landscape
1. Market Share Analysis, 2024
2. Market Structure
  1. Competition Intensity Mapping By Market
  2. Competition Dashboard
3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. Lonza Group AG
    1. Overview
    2. Segments and Deployments
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Thermo Fisher Scientific Inc.
  3. Samsung Biologics Co., Ltd.
  4. Boehringer Ingelheim International GmbH
  5. AGC Biologics, Inc.
  6. WuXi Biologics
  7. Patheon N.V.
  8. Catalent, Inc.
  9. AbbVie Inc.
  10. Avid Bioservices, Inc.
  11. Fujifilm Diosynth Biotechnologies
  12. Rentschler Biopharma SE
  13. KBI Biopharma (JSR Corporation)
  14. Cytovance Biologics
  15. Xpress Biologic
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

CMO/CDMO Biotechnology Market Size, Share, and Growth Forecast, 2025 - 2032

CMO/CDMO Biotechnology Market By Service Type (Standalone Services, Others), Product Type (Monoclonal Antibodies, Cell & Gene Therapies (CGTs), Others), Scale of Operation (Small Scale/Pilot Production, Large Scale/Commercial Manufacturing), and Regional Analysis for 2025 - 2032